Patents by Inventor Dovile Zilenaite

Dovile Zilenaite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12131481
    Abstract: We present a new method to automatically sample the tumour/stroma interface zone (IZ) from microscopy image analysis data. It first delineates the tumour edge using a set of explicit rules in grid-subsampled tissue areas; then the IZ of controlled width is sampled and ranked by the distance from the edge to compute TIL density profiles across the IZ. From this data, a set of novel Immunogradient indicators are computed to reflect TIL “gravitation” towards the tumour. We applied the method on CD8 immunohistochemistry images of surgically excised breast and colorectal cancers to predict overall patient survival. In both patient cohorts, we found strong and independent prognostic value of the Immunogradient indicators, outperforming methods currently available. We conclude that data-driven, automated, human operator-independent IZ sampling enables precise spatial immune response measurement in the tumour/host interaction frontline for prediction of disease and therapy outcomes.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 29, 2024
    Assignee: Vilnius University
    Inventors: Arvydas Laurinavicius, Allan Rasmusson, Ausrine Nestarenkaite, Dovile Zilenaite, Renaldas Augulis
  • Publication number: 20220138955
    Abstract: We present a new method to automatically sample the tumour/stroma interface zone (IZ) from microscopy image analysis data. It first delineates the tumour edge using a set of explicit rules in grid-subsampled tissue areas; then the IZ of controlled width is sampled and ranked by the distance from the edge to compute TIL density profiles across the IZ. From this data, a set of novel Immunogradient indicators are computed to reflect TIL “gravitation” towards the tumour. We applied the method on CD8 immunohistochemistry images of surgically excised breast and colorectal cancers to predict overall patient survival. In both patient cohorts, we found strong and independent prognostic value of the Immunogradient indicators, outperforming methods currently available. We conclude that data-driven, automated, human operator-independent IZ sampling enables precise spatial immune response measurement in the tumour/host interaction frontline for prediction of disease and therapy outcomes.
    Type: Application
    Filed: April 9, 2020
    Publication date: May 5, 2022
    Inventors: Arvydas Laurinavicius, Allan Rasmusson, Ausrine Nestarenkaite, Dovile Zilenaite, Renaldas Augulis